Our Approach

Our mission is to develop novel therapies with the potential to significantly improve the treatment of immune diseases and cancer by furthering the science behind drug development.

We are focused on developing ITK inhibition as a new approach to control the immune system, with a differentiated mechanism of action that targets T cells and other immune cells, which are critical to the immune response to both hematologic and solid cancers, as well as immune diseases.

In addition to ITK inhibition, we have developed a pipeline of investigational agents – both small molecules and antibodies – that are designed to precisely modulate molecular targets that are well-defined and measurable. This allows us to identify biomarkers to help select the patients who can benefit most. We evaluate our investigational medicines in intelligently-designed, rigorously-conducted clinical trials to:

• Assess their safety, tolerability and efficacy in patients
• Understand how they work at the biological level and confirm their mechanism of action
• Identify relevant biomarkers
• Increase clinical development success by first establishing monotherapy activity, followed by potential combinations with other standard of care therapies

We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.